Table 1

Characteristics and results of clinical studies on anti-IL-17 drugs

ReferenceStudy typePatients nDiseaseTreatmentResults
39 Phase 2130CDBRO
  • Worsening CD with BRO.

  • No statistically significant difference in CDAI response between BRO and placebo.

35 Phase 259CDSEC
  • 31% of early discontinuation.

  • Elevation of inflammatory markers (CRP, FC, CDAI).

  • 14 serious adverse events.

11 Phase 3226ASSECNo case of CD or UC
12 Phase 3290ASSECEIAR for CD: 0.4, for UC 0.5
13 Phase 3200ASSECIncidence: 0.8 per 100 PY
14 Phase 3274ASSECEAIR for CD: 0.6, for UC: 0.2
15 Phase 3219ASSECEIAR for CD : 0.7
17 Phase 3219ASSECEIAR for CD: 0.6, for UC: 0.6
19 Review of phase 3 studies4209PsOIXE
  • Three discontinuations for CD, 5 for UC.

  • Four exacerbations in patients with known CD.

  • 10 exacerbations in patients with known UC.

67 Systematic review and meta-analysis16 690PsO
  • 12 new IBD cases (anti-IL-17 group).

  • 0 new IBD cases (placebo group).

  • No increased risk of new IBD onset or diarrhoea under anti-IL-17 vs placebo (p=0.35).

68 Systematic review8742PsOIXE
  • Association with IBD exacerbation.

  • Caution in case of diagnosed IBD or personal history suggesting IBD.

69 Retrospective evaluation of pooled studies7355PsO
  • EAIRs in PsO: 0.13 for UC, 0.05 for CD and 0.01 for IC.

  • EAIRs in PsA: 0.08 for CD, 0.08 for UC and 0.05 for IC.

  • EAIRs in AS: 0.2 for CD, 0.4 for UC and 0.1 for IC.

  • SEC not associated with increased EAIRs over time.

70 Phase 3590ASSECPooled exposure-adjusted incidence rates from grade 3 and 4 for CD: 0.7/100 PY
71 Phase 3341ASIXEOne case of probable CD in the group with IXE every 2 weeks
  • AS, ankylosing spondylitis; BRO, brodalumab; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CRP, C reactive protein; EAIRs, exposure-adjusted incidence rates (per 100 patients years); FC, faecal calprotectin; IBD, inflammatory bowel disease; IC, indeterminate colitis; IL-17, interleukin-17; IXE, ixekizumab; PsA, psoriatic arthritis; PsO, psoriasis; PY, patient years; SEC, secukinumab; UC, ulcerative colitis.